Transplant outcomes by disease |
(CIBMTR data)
View larger version
|
Probability of survival after HLA-identical sibling transplants for ALL, age <20 years, 1998-2006, by disease status.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after HLA-identical sibling transplants for ALL, age >20 years, 1998-2006, by disease status.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(NMDP data)
View larger version
|
ALL: Survival of adult marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Lymphoblastic Leukemia (ALL) — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
ALL: Survival of pediatric marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Lymphoblastic Leukemia (ALL) — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
ALL: Survival of adult PBSC transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Lymphoblastic Leukemia (ALL) — NMDP Transplant Outcomes.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after HLA-identical sibling myeloablative transplants for AML, 1998-2006, by disease status.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after autotransplants for AML, age <20 years, 1998-2006, by disease status.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after autotransplants for AML, age >20 years, 1998-2006, by disease status.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(NMDP data)
View larger version
|
AML: Survival of adult marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
AML: Survival of pediatric marrow transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
AML: Survival of adult PBSC transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
AML: Survival of transplant patients >55 years old, myeloablative conditioning, PBSC and marrow, by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
AML: Survival of transplant patients >55 years old, non-myeloablative conditioning, PBSC and marrow, by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Acute Myelogenous Leukemia — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
Acute leukemias: Survival of pediatric cord blood transplant patients, all preparative regimens, by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after transplants for CML in chronic phase, 1998-2006, by donor type and disease duration.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(NMDP data)
View larger version
|
CML: Survival of adult marrow myeloablative transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Chronic Myelogenous Leukemia (CML) — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
CML: Survival of adult PBSC myeloablative transplant patients by disease stage, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Chronic Myelogenous Leukemia (CML) — NMDP Transplant Outcomes.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after autotransplants for Hodgkin disease, 1998-2006, by disease status.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(NMDP data)
View larger version
|
Inherited immune system disorders: Overall survival of pediatric marrow transplant patients with severe combined immunodeficiency (SCID) and Wiskott-Aldrich syndrome (WAS), unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Immune Deficiencies and Metabolic Disorders — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
Inherited metabolic disorders: Survival of pediatric marrow transplant patients with Hurler syndrome, adrenoleukodystrophy (ALD)/metachromatic dystrophy (MLD), unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Immune Deficiencies and Metabolic Disorders — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
Non-malignant diseases: Survival of pediatric cord blood myeloablative transplant patients, unrelated donor transplants facilitated by the NMDP, 1998-2006.
Diseases include histiocytic disorders, thalassemia major, severe combined immunodeficiency (SCID), inherited metabolic disorders, inherited platelet disorders, severe aplastic anemia, and Fanconi anemia.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after hematopoietic stem cell transplants for multiple myeloma, 1998-2006, by donor type.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after allogeneic transplants for myelodysplastic syndromes (MDS) age <20 years, 1998-2006, by disease status and donor type.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after allogeneic transplants for myelodysplastic syndromes (MDS) age >20 years, 1998-2006, by disease status and donor type.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(NMDP data)
View larger version
|
MDS: Survival of adult marrow myeloablative transplant patients by FAB classification, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
MDS: Survival of adult PBSC myeloablative transplant patients by FAB classification, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
MDS: Survival of adult marrow and PBSC transplant patients by age (18-54 yrs. or >55 yrs.), unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
MDS RAEB/RAEB-T: Survival of adult PBSC and marrow transplant patients by conditioning regimen, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Myelodysplastic Syndromes (MDS) — NMDP Transplant Outcomes.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after autotransplants for diffuse large B-cell lymphoma, 2000-2006, by disease status.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after autotransplants for follicular lymphoma, 2000-2006, by disease status.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after HLA-identical sibling allotransplants for follicular lymphoma, 1998-2006, by disease status and conditioning regimen.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(CIBMTR data)
View larger version
|
Probability of survival after HLA-identical sibling allotransplants for diffuse large cell lymphoma, 1998-2006, by disease status and conditioning regimen.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage.
|
|
(NMDP data)
View larger version
|
NHL: Survival of adult non-myeloablative transplant patients by cell source (PBSC or marrow), unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Non-Hodgkin's Lymphoma (NHL) — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
Severe aplastic anemia: Survival of marrow transplant patients by age (adult or pediatric), unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Severe Aplastic Anemia & Fanconi Anemia — NMDP Transplant Outcomes.
|
|
(NMDP data)
View larger version
|
Fanconi anemia: Survival of pediatric reduced-intensity marrow transplant patients, unrelated donor transplants facilitated by the NMDP, 1998-2006.
For discussion of these data, see Transplant Outcomes by Disease and Disease Stage and Severe Aplastic Anemia & Fanconi Anemia — NMDP Transplant Outcomes.
|
|
Diseases treated with transplant |
(CIBMTR data)
View larger version
|
Indications for hematopoietic stem cell transplantation in North America, 2005.
For discussion of these data, see Diseases Treatable by Hematopoietic Cell Transplant.
|
|
(CIBMTR data)
View larger version
|
Indications for allogeneic hematopoietic stem cell transplantation, worldwide, 2005.
For discussion of these data, see Diseases Treatable by Hematopoietic Cell Transplant.
|
|
Number of transplants facilitated by the NMDP |
(NMDP data)
View larger version
|
NMDP transplants by cell source, adult recipients, 1988-2008. (NMDP data is fiscal year data through September 30, 2008)
For discussion of these data, see Trends in Allogeneic Transplants.
|
|
(NMDP data)
View larger version
|
NMDP transplants by cell source, pediatric recipients, 1988-2008.
For discussion of these data, see Trends in Allogeneic Transplants.
|
|
(NMDP data)
View larger version
|
NMDP transplants by patient diagnosis, malignant diseases, 1998-2008.
|
|
(NMDP data)
View larger version
|
NMDP transplants by patient diagnosis, non-malignant diseases, 1998-2008.
|
|
(NMDP data)
View larger version
|
NMDP transplants by patient age and year, 1997-2008.
|
|
Sources of cells for transplant |
(CIBMTR data)
View larger version
|
Autologous stem cell sources by recipient age, 1997-2006.
For discussion of these data, see Hematopoietic Cell Sources Tailored to the Patient.
|
|
(CIBMTR data)
View larger version
|
Allogeneic stem cell sources by recipient age, 1997-2006.
For discussion of these data, see Hematopoietic Cell Sources Tailored to the Patient.
|
References
- Weisdorf D, (Ed.). The National Marrow Donor Program reports to the community on 20 years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14(9, Suppl. 3):1-60.
http://www.bbmt.org/issues/contents?issue_key=S1083-8791(08)X0009-6 |